Asymmetries have been furthered by the financial power of, and alliances with, the pharmaceutical industry. Where financial resources for research and innovation are absent, the industry fills the gap with little transparency in drug approval processes or in doubtful relationships with health-care professionals and providers. That context illustrates how overreliance in policy on the biomedical model has gone too far and is now so resistant to change.
Legal status
Non-negotiated soft law
Body
Special Rapporteur on the right of everyone to the enjoyment of the highest attainable standard of physical and mental health